Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Holdings Decreased by HMS Capital Management LLC

HMS Capital Management LLC reduced its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 11.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,816 shares of the medical equipment provider’s stock after selling 733 shares during the quarter. HMS Capital Management LLC’s holdings in Zimmer Biomet were worth $614,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of ZBH. Stonebridge Financial Group LLC bought a new stake in shares of Zimmer Biomet during the fourth quarter valued at about $25,000. Dunhill Financial LLC raised its stake in shares of Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 218 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in shares of Zimmer Biomet during the third quarter valued at about $28,000. Brooklyn Investment Group bought a new stake in Zimmer Biomet in the third quarter worth about $35,000. Finally, Kentucky Trust Co bought a new stake in Zimmer Biomet in the fourth quarter worth about $39,000. 88.89% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Truist Financial reiterated a “hold” rating and issued a $113.00 price target (down from $118.00) on shares of Zimmer Biomet in a research report on Monday. Wells Fargo & Company boosted their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Stifel Nicolaus boosted their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Raymond James dropped their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Finally, Barclays dropped their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research note on Monday. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, Zimmer Biomet has an average rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $98.98 on Thursday. The stock has a market cap of $19.70 billion, a PE ratio of 22.24, a price-to-earnings-growth ratio of 1.83 and a beta of 1.02. The stock’s 50-day moving average is $106.91 and its two-hundred day moving average is $107.91. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $97.69 and a fifty-two week high of $133.90. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.70.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the business posted $2.20 earnings per share. As a group, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.25 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were paid a $0.24 dividend. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.97%. Zimmer Biomet’s payout ratio is 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.